Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Kimberly R. Doherty"'
Autor:
Kimberly R Doherty, Cayman A Stephen, Kyle R Siegel, Michelle M Johnson, Melissa D Zammit, Peter B Senese, Michael R Gralinski
Publikováno v:
Circulation. 144
Rats develop translatable pulmonary arterial hypertension (PAH) after exposure to the VEGF antagonist semaxanib (SU5416) concurrent with hypoxia. Sildenafil is used clinically for PAH and as a positive control in this preclinical model. A longitudina
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c227da7a2f445ffb22eb6cc420db6f04
https://doi.org/10.1161/circ.144.suppl_1.14009
https://doi.org/10.1161/circ.144.suppl_1.14009
Autor:
Patricia Trusk, Diarmuid M. Moran, Scott A. Shell, Dominique R. Talbert, Kimberly R. Doherty, Sarah S. Bacus
Publikováno v:
Toxicology and Applied Pharmacology. 285:51-60
Safety pharmacology studies that evaluate new drug entities for potential cardiac liability remain a critical component of drug development. Current studies have shown that in vitro tests utilizing human induced pluripotent stem cell-derived cardiomy
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::abf1fd0df5913495978e6804a9684d06
https://doi.org/10.1016/j.taap.2015.03.008
https://doi.org/10.1016/j.taap.2015.03.008
Publikováno v:
Journal of Pharmacological and Toxicological Methods. 99:106595
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d7f11ad0ac43404eb6bd782f3d0c2774
https://doi.org/10.1016/j.vascn.2019.05.086
https://doi.org/10.1016/j.vascn.2019.05.086
Autor:
Sarah S. Bacus, Dominique R. Talbert, Scott A. Shell, Kimberly R. Doherty, Diarmuid M. Moran, Patricia Trusk
Publikováno v:
Toxicological sciences : an official journal of the Society of Toxicology. 143(1)
Ponatinib, a multi-targeted TKI and potent pan-ABL inhibitor, approved for the treatment of Ph þ ALL and CML, was temporarily withdrawn from the U.S. market due to severe vascular adverse events. Cardiac-specific toxicities including myocardial infa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c639dafeee61e0e473fcdf719cf9fd9e
https://pubmed.ncbi.nlm.nih.gov/25304212
https://pubmed.ncbi.nlm.nih.gov/25304212
Autor:
Sarah S. Bacus, Scott A. Shell, Robert L. Wappel, Patricia Trusk, Diarmuid M. Moran, Arthur Brown, James Kramer, Dominique R. Talbert, Kimberly R. Doherty
Publikováno v:
Toxicology and applied pharmacology. 272(1)
Tyrosine kinase inhibitors (TKi) have greatly improved the treatment and prognosis of multiple cancer types. However, unexpected cardiotoxicity has arisen in a subset of patients treated with these agents that was not wholly predicted by pre-clinical
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3442c89697ec203a2c7b8d8246513dae
https://pubmed.ncbi.nlm.nih.gov/23707608
https://pubmed.ncbi.nlm.nih.gov/23707608
Publikováno v:
Journal of Pharmacological and Toxicological Methods. 75:194
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::fd20b19bbb6ae49a51e7151316896f97
https://doi.org/10.1016/j.vascn.2015.08.122
https://doi.org/10.1016/j.vascn.2015.08.122
Publikováno v:
Cancer Research. 75:2611-2611
The human epidermal growth factor receptor 2 (HER2) oncogene is amplified and overexpressed in 25 to 30% of breast cancers and is associated with poor prognosis. Currently, two HER2-targeting agents have been FDA-approved for the treatment of these b
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5b007dc17d649c9d625d87c4cc8b9201
https://doi.org/10.1158/1538-7445.am2015-2611
https://doi.org/10.1158/1538-7445.am2015-2611
Autor:
Diarmuid M. Moran, Patricia Trusk, Dominique R. Talbert, Kimberly R. Doherty, Scott A. Shell, Sarah S. Bacus
Publikováno v:
Cancer Research. 74:3674-3674
Although tyrosine kinase inhibitors (TKI) have greatly improved the treatment and prognosis of multiple cancer types, unexpected clinical cardiotoxicity has occurred with some of these agents that was not predicted by standard preclinical toxicity as
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::508a006c7a0565f75c0b4a1d3e083055
https://doi.org/10.1158/1538-7445.am2014-3674
https://doi.org/10.1158/1538-7445.am2014-3674
Autor:
Robert Wappell, Dominique R. Talbert, Kimberly R. Doherty, Sarah S. Bacus, Scott A. Shell, Diarmuid M. Moran, Patricia Trusk
Publikováno v:
Molecular Cancer Therapeutics. 12:C280-C280
Tyrosine Kinase Inhibitors (TKI) have greatly improved the treatment and prognosis of multiple cancer types. However unexpected clinical cardiotoxicity has been shown with some of these agents that was not wholly predicted by current preclinical toxi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4e7b4181b2b14fd71b389e89d2b70b4d
https://doi.org/10.1158/1535-7163.targ-13-c280
https://doi.org/10.1158/1535-7163.targ-13-c280
Autor:
Dominique R. Talbert, Robert L. Wappel, Kimberly R. Doherty, Sarah S. Bacus, Patricia Trusk, Scott A. Shell, Arthur Brown, Diarmuid M. Moran, James W. Kramer
Publikováno v:
Cancer Research. 73:4423-4423
Tyrosine kinase inhibitors (TKi) have greatly improved the treatment and prognosis of multiple cancer types. However, unexpected cardiotoxicity has arisen that was not wholly predicted by current FDA mandated pre-clinical tests. Thus a more robust to
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::85bad435317304f50dfc2e7b1a3bf6ec
https://doi.org/10.1158/1538-7445.am2013-4423
https://doi.org/10.1158/1538-7445.am2013-4423